Post-Operative Pain - Pipeline Review, H2 2017

Date: July 11, 2017
Pages: 191
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until September 1, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PB52535144BEN
Leaflet:

Download PDF Leaflet

Post-Operative Pain - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain - Pipeline Review, H2 2017, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.

Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 10, 16, 8, 14, 3 and 2 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 1 molecules, respectively.

Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Post-Operative Pain - Overview
Post-Operative Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Post-Operative Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post-Operative Pain - Companies Involved in Therapeutics Development
Abide Therapeutics Inc
AcelRx Pharmaceuticals Inc
Adynxx Inc
AngioChem Inc
Aoxing Pharmaceutical Company Inc
Camurus AB
Cara Therapeutics Inc
Center Laboratories Inc
Colby Pharmaceutical Company
Cytogel Pharma LLC
Dompe Farmaceutici SpA
DURECT Corp
Eupraxia Pharmaceuticals Inc
EyeGate Pharmaceuticals Inc
Fujimoto Pharmaceutical Corp
GW Pharmaceuticals Plc
Heron Therapeutics Inc
Immupharma Plc
Innocoll AG
Insys Therapeutics Inc
Lipocure Ltd
Liquidia Technologies Inc
Medtronic Plc
Mundipharma International Ltd
Novartis AG
Orion Oyj
Pacira Pharmaceuticals Inc
PainReform Ltd
PhytoHealth Corp
PixarBio Corp
Proteus SA
Recro Pharma Inc
Relmada Therapeutics Inc
Serina Therapeutics Inc
SteadyMed Therapeutics Inc
Teikoku Pharma USA Inc
The Medicines Company
Trevena Inc
Xigen SA
Post-Operative Pain - Drug Profiles
(bupivacaine hydrochloride + meloxicam) ER - Drug Profile
(buprenorphine hydrochloride + granisetron hydrochloride) ER - Drug Profile
A-100 - Drug Profile
ABD-1970 - Drug Profile
ANG-2002 - Drug Profile
ARX-04 - Drug Profile
AYX-1 - Drug Profile
brimapitide - Drug Profile
bupivacaine hydrochloride - Drug Profile
bupivacaine hydrochloride - Drug Profile
bupivacaine hydrochloride - Drug Profile
bupivacaine hydrochloride - Drug Profile
bupivacaine hydrochloride SR - Drug Profile
bupivacaine hydrochloride SR - Drug Profile
buprenorphine hydrochloride - Drug Profile
CAM-2048 - Drug Profile
carbamazepine - Drug Profile
CPC-111 - Drug Profile
CPC-123 - Drug Profile
CT-044 - Drug Profile
Cyt-1010 - Drug Profile
dexamethasone acetate - Drug Profile
dexmedetomidine hydrochloride - Drug Profile
DF-2755A - Drug Profile
difelikefalin - Drug Profile
Drug to Agonize MOR1 for Pain - Drug Profile
ECP-1014 - Drug Profile
fadolmidine hydrochloride - Drug Profile
fentanyl - Drug Profile
gonyautoxin - Drug Profile
HTX-009 - Drug Profile
HYLP-002 - Drug Profile
IPP-102199 - Drug Profile
ketorolac tromethamine - Drug Profile
lacosamide - Drug Profile
levorphanol tartrate ER - Drug Profile
MDT-10013 - Drug Profile
meloxicam - Drug Profile
meloxicam ER - Drug Profile
MR-309 - Drug Profile
nabiximols - Drug Profile
nalbuphine hydrochloride - Drug Profile
neosaxitoxin - Drug Profile
oliceridine - Drug Profile
PMZ-2010 - Drug Profile
RBM-004 - Drug Profile
ropivacaine - Drug Profile
ropivacaine ER - Drug Profile
SAF-312 - Drug Profile
SER-226 - Drug Profile
Small Molecule for Post-Operative Pain - Drug Profile
Small Molecules to Inhibit COX for Postoperative Acute Pain - Drug Profile
sufentanil citrate - Drug Profile
tilidine hydrochloride - Drug Profile
tramadol hydrochloride - Drug Profile
URB-937 - Drug Profile
VVZ-149 - Drug Profile
XEN-105 - Drug Profile
Post-Operative Pain - Dormant Projects
Post-Operative Pain - Discontinued Products
Post-Operative Pain - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Post-Operative Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Post-Operative Pain - Pipeline by Abide Therapeutics Inc, H2 2017
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc, H2 2017
Post-Operative Pain - Pipeline by Adynxx Inc, H2 2017
Post-Operative Pain - Pipeline by AngioChem Inc, H2 2017
Post-Operative Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017
Post-Operative Pain - Pipeline by Camurus AB, H2 2017
Post-Operative Pain - Pipeline by Cara Therapeutics Inc, H2 2017
Post-Operative Pain - Pipeline by Center Laboratories Inc, H2 2017
Post-Operative Pain - Pipeline by Colby Pharmaceutical Company, H2 2017
Post-Operative Pain - Pipeline by Cytogel Pharma LLC, H2 2017
Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA, H2 2017
Post-Operative Pain - Pipeline by DURECT Corp, H2 2017
Post-Operative Pain - Pipeline by Eupraxia Pharmaceuticals Inc, H2 2017
Post-Operative Pain - Pipeline by EyeGate Pharmaceuticals Inc, H2 2017
Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corp, H2 2017
Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc, H2 2017
Post-Operative Pain - Pipeline by Heron Therapeutics Inc, H2 2017
Post-Operative Pain - Pipeline by Immupharma Plc, H2 2017
Post-Operative Pain - Pipeline by Innocoll AG, H2 2017
Post-Operative Pain - Pipeline by Insys Therapeutics Inc, H2 2017
Post-Operative Pain - Pipeline by Lipocure Ltd, H2 2017
Post-Operative Pain - Pipeline by Liquidia Technologies Inc, H2 2017
Post-Operative Pain - Pipeline by Medtronic Plc, H2 2017
Post-Operative Pain - Pipeline by Mundipharma International Ltd, H2 2017
Post-Operative Pain - Pipeline by Novartis AG, H2 2017
Post-Operative Pain - Pipeline by Orion Oyj, H2 2017
Post-Operative Pain - Pipeline by Pacira Pharmaceuticals Inc, H2 2017
Post-Operative Pain - Pipeline by PainReform Ltd, H2 2017
Post-Operative Pain - Pipeline by PhytoHealth Corp, H2 2017
Post-Operative Pain - Pipeline by PixarBio Corp, H2 2017
Post-Operative Pain - Pipeline by Proteus SA, H2 2017
Post-Operative Pain - Pipeline by Recro Pharma Inc, H2 2017
Post-Operative Pain - Pipeline by Relmada Therapeutics Inc, H2 2017
Post-Operative Pain - Pipeline by Serina Therapeutics Inc, H2 2017
Post-Operative Pain - Pipeline by SteadyMed Therapeutics Inc, H2 2017
Post-Operative Pain - Pipeline by Teikoku Pharma USA Inc, H2 2017
Post-Operative Pain - Pipeline by The Medicines Company, H2 2017
Post-Operative Pain - Pipeline by Trevena Inc, H2 2017
Post-Operative Pain - Pipeline by Xigen SA, H2 2017
Post-Operative Pain - Dormant Projects, H2 2017
Post-Operative Pain - Dormant Projects, H2 2017 (Contd..1), H2 2017
Post-Operative Pain - Dormant Projects, H2 2017 (Contd..2), H2 2017
Post-Operative Pain - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Post-Operative Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Skip to top


Ocular Pain - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 70 pages

Ask Your Question

Post-Operative Pain - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: